CalciMedica regained compliance with Nasdaq’s minimum bid-price requirement after its common stock maintained a closing bid of at least $1.00 per share from August 31 through September 14, 2026. The company said it has no outstanding deficiency notices from Nasdaq, removing the specific listing deficiency identified in March.
Key Highlights
- Nasdaq notified CalciMedica on September 15 that its common stock met the required bid-price standard from August 31 through September 14.
- The Nasdaq notice CalciMedica received on March 16 concerned a minimum bid price below $1.00 per share.
- CalciMedica said it has no outstanding deficiency notices from Nasdaq as of September 16.
CalciMedica, Inc. (NASDAQ: CALC) has regained compliance with Nasdaq’s minimum bid-price requirement after its common stock recorded a closing bid of at least $1.00 per share through the required review period. Nasdaq’s Listing Qualifications Department notified the company that it had regained compliance, and the company had no outstanding deficiency notices as of September 16, 2026.
Nasdaq Confirms $1.00 Bid-Price Compliance
The issue began with a Nasdaq notice received on March 16, 2026, stating that CalciMedica’s minimum bid price for its common stock had been below the $1.00-per-share minimum required under Listing Rule 5550(a)(2) for 30 consecutive Business days. Nasdaq later determined that the stock’s closing bid price had been at $1.00 per share or higher from August 31 through September 14, 2026. The company received that determination on September 15.
FAQs
Q: What Nasdaq requirement did CalciMedica regain compliance with?
A: CalciMedica regained compliance with Nasdaq Listing Rule 5550(a)(2), which sets the minimum bid-price requirement for its common stock. The rule required a minimum bid price of $1.00 per share.
Q: When did CalciMedica meet Nasdaq’s minimum bid-price standard?
A: Nasdaq determined that CalciMedica’s common stock had a closing bid of $1.00 per share or higher from August 31 through September 14, 2026.
Q: Does CalciMedica have any outstanding Nasdaq deficiency notices?
A: CalciMedica reported that it had no outstanding deficiency notices from Nasdaq.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.